Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Deconstructing the Electrode-Electrolyte Interface by Novel NMR Methodology (SEISPY)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Physical and Analytical Chemical Sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: Israel
Call: ERC CONSOLIDATOR GRANTS (ERC-2023-COG, 2023)
Start date: 2025-01-01
End date: 2029-12-31
Duration (months): 60.0
Total project cost (EUR): 2228750.0
EU funding (EUR): 2228750.0
Participants: 1
Project status: SIGNED

More efficient rechargeable batteries must be developed for utilizing sustainable energy sources and stopping the rapidly advancing climate change. The current technology cannot be merely extended for the next-generation storage systems. New approaches are required, especially for understanding and controlling the complex chemistry at the electrode-electrolyte interface. It has already been established that such control can, in principle, be realized by the solid electrolyte interphase (SEI), a stable passivating layer formed on the electrode. Such a layer should enable continuous transport of ions across it, but the fundamental understanding of what SEI components and architectures may give rise to such transport is not yet available. The ultimate goal of this ERC project is to establish structure-function correlation for the SEI by implementing methodologies for directly probing interfaces at the atomic-molecular level and for guiding the design of novel interphases. We will achieve this goal by introducing to materials science a set of NMR 'tools' based on chemical exchange saturation transfer (CEST), commonly used to study dynamics in biomolecular-NMR. Here we propose to develop variants of CEST to probe ion dynamics across the SEI. Implementing these new approaches in situ, we will disentangle the multistep transport process at the electrolyte-SEI-electrode interfaces. Coupled with sensitivity enhancement by Dynamic Nuclear Polarization from inherent polarization sources, we will identify the SEI components participating in the ion exchange processes. Integrating our results with the battery performance, we will determine the pathways and bottlenecks for transport across the SEI. Applying advanced NMR methods combined with controlled surface chemistry to state-of-the-art battery materials, such as lithium and beyond metal anodes, high-energy cathodes and composite electrolytes, we will establish design rules for next-generation energy storage systems.

Keywords: rechargeable batteries,solid electrolyte interphase,ion transport,solid state nmr spectroscopy,dynamic nuclear polarization,metal anodes,high energy cathodes,solid electrolytes
Fast track to cleaner, healthier urban Aerosols by market ready Solutions of retrofit Filtration Devices for tailpipe, brake systems and closed environments (AeroSolfd)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Mobility
Destination: Clean and competitive solutions for all transport modes
Action type: Innovation actions
Countries involved: Germany,Spain,Denmark,Netherlands,Bulgaria,Portugal,Italy,Switzerland,Slovenia
Call: Development and demonstration of cost affordable and adaptable retrofit solutions for tailpipe and brake polluting emissions (HORIZON-CL5-2021-D5-01, 2021)
Start date: 2022-05-01
End date: 2025-08-31
Duration (months): 40.0
Total project cost (EUR): 5955844.55
EU funding (EUR): 4999588.56
Participants: 19
Project status: SIGNED

Emissions of the existing gasoline engines and brakes of the commercial vehicle fleets in Europe relate to health problems and death of annually >1,45 Mio. people. For the next decades, these vehicles will continue populating the roads, emitting PM/PN exhaust particles and toxic secondary emissions. For immediate reduction, retrofit solutions for tailpipe and brake emissions must be brought to TRL 8 and introduced to the market by 2025. Timing is crucial: Retrofits are transition technologies until full electrification of Europe’s transport fleet. Even beyond, brake retrofits play an important role in the electrified fleet. Quick wins in the reduction of the overall footprint of the existing fleets can be realised by using our 3 retrofits for tailpipe, brake and closed environments: 95% of PM2.5 and 80% of toxic secondary emissions using an innovative Gasoline Particle Filter, 60% of NOx exhaust emissions replacing the aged TWC by original equipment, 90% of the brake particles of long-lived road transport assets using a passive BDPF, 90% of particles in closed environments (bus stops, tunnels, metro stations) using a special designed and enhanced stationary air purifier. To create credible key messages for clients, citizens and policy, we perform lighthouse demo activities: 1) tailpipe retrofit: 1.000 vehicles in 2 climate zones (Germany + Israel) for 4 representative engine type families, 2) brake retrofit: Define emission fingerprints for the public transport of the cities of Valladolid, Ancona, Fermo and Sofia and > 35000 km lab testing on dynamometer and > 8000 km real driving, 3) air purifier retrofit for closed environments: 3 underground stations (Sofia, 2x Lisbon) with > 130000 commuters and Valladolid central bus depot with > 150 buses. For market preparation we will reach >4.000 citizens and policy makers from EU KOM level and >8 EU countries. We unite world leading industry, renowned scientific institutes and lighthouse demo sites in 8 European countries

Keywords: retrofit solutions for tailpipe,non tailpipe and brake emissions
CUSTOM-MADE NEURONS FOR CELL THERAPY IN PARKINSON’S AND HUNTINGTON’S DISEASE (Custom-Made)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Synergy grants
Action type: ERC actions
Countries involved: Italy,Sweden,Denmark
Call: ERC SYNERGY GRANTS (ERC-2024-SyG, 2024)
Start date: 2025-11-01
End date: 2031-10-31
Duration (months): 72.0
Total project cost (EUR): 10000000.0
EU funding (EUR): 10000000.0
Participants: 4
Project status: SIGNED

The rising incidence of age-associated neurodegenerative diseases, due to increased life expectancy, poses a challenge to the brain's limited regenerative capabilities. Stem cell-based therapies offer promise for addressing crucial neuron loss, particularly in Parkinson’s and Huntington’s diseases (PD and HD). Ongoing first-generation stem cell trials, replacing damaged neurons with healthy ones, represent a notable advancement. However, their impact is constrained by a ‘one-cell-fits-all’ generic therapy that does not take in account the diverse clinical needs due to variations in disease etiology, stage, patient heterogeneity, and daily fluctuations in graft requirements. CUSTOM-MADE is a transformative initiative advancing knowledge and crafting a tailored portfolio of stem cell products for individual patients or patient subgroups, notably targeting PD and HD. Integrating stem cell technologies, genomics and bioengineering, CUSTOM-MADE develops rational graft composites of therapeutic neurons and complementary cells to meet the clinical needs of individual patients. Moving into preclinical animal models, the project refines graft connectivity and functional recovery post-transplantation. A groundbreaking leap involves modeling circuitry reconstruction in a fully humanized 3D in-vitro bioengineered system - the connectoids, allowing detailed studies at cellular and molecular levels for defining factors controlling correct and functional graft integration. For increased translatability, CUSTOM-MADE pioneers the generation of cell products whose activity can be self-regulated or tuned to the patients’ individual requirements. The project implements strategic measures to shield grafts from pathology and introduces the innovative concept of grafted cells exhibiting disease-modifying activity. In essence, CUSTOM-MADE drives the field toward customized stem-cell therapies for PD and HD, marking a paradigm shift in the treatment landscape of neurodegenerative diseases.

Keywords: connectoids,biosensors,chemogenetics,activity regulators,parkinson s disease,huntington s disease
Backbone-Optimized OligonucleotideS for Therapeutics (BOOST)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Denmark
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-04-01
End date: 2026-03-31
Duration (months): 24.0
Total project cost (EUR): 214934.4
EU funding (EUR): 214934.4
Participants: 1
Project status: SIGNED

Therapeutic oligonucleotides (ONs) have recently gained increasing importance as new drugs. While conventional drugs are limited to targeting proteins, oligonucleotides are able to target diseases upstream at the mRNA level. This specificity in combination with their easy design renders them highly valuable. Furthermore, their applications are limitless, involving treatment of so-called undruggable diseases. The bottleneck in the development of new therapeutic oligonucleotides lies in the efficient synthesis of modified ONs. Often, these modifications require multi-step syntheses and are laborious resulting in a time-consuming process of drug development. Additionally, these modifications often negatively impact physiological and biological properties. In our proposal, “Backbone-Optimized OligonucleotideS for Therapeutics” (BOOST), we outline a methodology for efficiently modifying oligonucleotides. Key to success will be the development of novel reagents capable of intercepting solid-phase oligonucleotide synthesis due to their high reaction rate. This will enable rapid evaluation of mono- and multiple-modified oligonucleotides to assess their physiological and biological properties. Furthermore, the introduction of multiple functionalities will become possible. BOOST will serve as a new platform for designing therapeutic antisense oligonucleotides (ASOs) and siRNA. As a proof of concept, we will evaluate the most promising modified oligonucleotides in biological settings.

Keywords: oligonucleotide backbone modifications solid phase oligonucleotide synthesis
Disruptive and high accuracy test for early colorectal cancer detection in blood (PreveCol)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Spain
Call: Strategic Digital and Health Technologies (HORIZON-EIC-2021-ACCELERATORCHALLENGES-01, 2021)
Start date: 2022-08-01
End date: 2025-03-31
Duration (months): 32.0
Total project cost (EUR): 3567954.55
EU funding (EUR): 2497568.0
Participants: 1
Project status: CLOSED

AMADIX is a leading molecular diagnostics company, led by Rocío Arroyo, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Colorectal cancer (CRC) is the 2nd leading cause of cancer-related deaths worldwide. Most of these cancers and deaths could have been prevented by increasing the use of recommended screening tests that detect premalignant lesions, called advanced adenomas. Colonoscopy is the gold standard screening method, although it is an invasive and expensive procedure. AMADIX has previously developed an innovative blood-based test for CRC diagnosis (ColoFast), based on an initial combination of cutting-edge biomarkers (micro-RNAs) and validated in +1,000 samples. Indicated to screen healthy population from 50 to 85 years old,has shown superior performance in early cancer detection than any of the tests commercialized, better compliance and cost-effectiveness and is being validated in a European prospective study with 3,100 patients (recruitment concluded) granted by SME Phase 2 with €2.8M. AMADIX has identified new promising biomarkers to be incorporated to the initial signature, to improve the diagnostic performance. AMADIX has taken advantage of the potential of Artificial Intelligence and Big Data to identify CRC risk factors from the patients’ clinical records and develop diagnostic prediction models. Our goal is to validate this new signature, PreveCol, more accurate than the initial combination, based on different types of biomarkers, followed by its commercialization as LDT and as IVD kit. In addition, a risk factors-based algorithm will be incorporated, enabling to predict and identify individuals with a high risk of developing CRC or premalignant polyps, even if they are younger than 50 years old, improving their survival consequently. AMADIX expects to reach between 2023-2032 accumulated revenues of €1,997M from the commercialization of PreveCol in Europe and USA.

Keywords: colorectal cancer,algorithm,artificial intelligence,life expectancy,healthcare,cancer,biotechnology,molecular biology,big data
Repetition and Aesthetic Evolution in Post-Soviet Post-Punk: From Kino to 2010s Cold Wave (KCW)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: United Kingdom
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-05-06
End date: 2027-05-05
Duration (months): 24.0
Total project cost (EUR): 276187.92
EU funding (EUR): 276187.92
Participants: 1
Project status: SIGNED

In the late 2010s, there was a resurgence in the global popularity of Russian and Belarusian post-punk bands, particularly those within the 'Cold Wave' subgenre. This post-Soviet music bears a strong resemblance to that of Kino, the iconic Soviet band that defined youth music culture during the perestroika era (1985-1991). Kino’s status was solidified as legendary after the tragic death of its charismatic singer, Viktor Tsoi, in a car accident in August 1990. This project aims to analyze the musical evolution and cultural significance of post-punk music in Russia and Belarus, focusing particularly on the 'Cold Wave' subgenre and its connections to Kino and contemporary post-Soviet music. The research will begin with a musicological analysis to highlight the differences between Kino and UK post-punk bands of the 1980s, as well as between Kino and post-Soviet Cold Wave bands of the 2010s. The study will focus on the concept of 'discursivity' as shaped by the guitar, examining how this musical element connects Kino to post-Soviet Cold Wave music while differentiating it from the UK Cold Wave. The music of Kino and post-Soviet Cold Wave is more aligned with Richard Middleton's idea of “discursive repetition” than with “musematic repetition,” which is more characteristic of the UK Cold Wave. The project will explore how this form of repetition, as a musical material, interacts with other elements within recordings. Furthermore, the research seeks to move beyond prevailing interpretations of Russian rock that are primarily focused on lyrics. It will re-examine the relationship between music and lyrics, developing innovative methodologies for popular music analysis. The project also intends to critically reinterpret Adornian socio-musicological concepts within the context of popular music, advancing into an interdisciplinary research approach that bridges sociology, philosophy, linguistics, cultural studies, and other related fields.

Keywords: popular music studies,repetition,musical material,adorno,soviet and post soviet post punk,cold wave,kino
Subtype as a key to reduce heterogeneity of treatment effects in major depressive disorder (SUBTREAT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Sweden
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2022-10-01
End date: 2027-09-30
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: SIGNED

Major depressive disorder (MDD) is a leading contributor to disability and suicide. It is the most costly brain disorder in Europe. Although multiple treatments are of proven efficacy, individual responses to treatments vary considerably and MDD recurrence is common. There is considerable motivation to improve treatment regimen for individuals with MDD. However, it has been challenging because of the fundamental lack of understanding about the causes of variable treatment outcomes. MDD is widely accepted as a heterogeneous disorder; yet, most research strategies effectively consider MDD as a single disorder. Progress in understanding the variable treatment response will depend on “patient stratification”, i.e., identifying and accounting for patient heterogeneity when evaluating treatment efficacy. SUBTREAT proposes a unique direction which considers subtype as the key to link aetiological and treatment effect heterogeneity. Our approach is to break down the heterogeneous treatment outcomes of MDD into more narrowly defined subtypes with divergent aetiologies. Specially, I propose three work packages: 1) dissect treatment heterogeneity across subtypes; a particularly innovative aspect of SUBTREAT is that we will use advanced data science approaches to identify novel subtypes which correlate with differential treatment outcomes; 2) determine divergent causes underlying MDD subtypes; we will comprehensively investigate causes at three levels including genetic and causal epidemiological risk factors, and brain cell types; 3) develop a novel prediction algorithm for treatment outcomes stratified by patient subgroups. SUBTREAT will illuminate the causes of MDD subtypes and the principal patterns of how subtypes contribute to differential long-term treatment outcomes. SUBTREAT findings will promote targeted drug development and treatment optimization for patient subgroups to achieve precision psychiatry.

Keywords: major depressive disorder,heterogeneity,treatment outcome,subtype,genetics,cell type,prediction,machine learning
Probing Gauge Symmetries and Gauge-Matter Interactions using Tensor Networks (GaMaTeN)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Fundamental Constituents of Matter
Panel description: Particle, nuclear, plasma, atomic, molecular, gas, and optical physics
Countries involved: Belgium
Call: ERC CONSOLIDATOR GRANTS (ERC-2023-COG, 2023)
Start date: 2024-09-01
End date: 2029-08-31
Duration (months): 60.0
Total project cost (EUR): 1997500.0
EU funding (EUR): 1997500.0
Participants: 1
Project status: SIGNED

We are in the midst of the second quantum revolution. Highly entangled quantum matter is being discovered, engineered, controlled and probed across a wide range of scales and conditions; quantum platforms are being used to emulate other quantum systems. The ability to simulate the quantum world on classical computers has been instrumental in guiding, validating and diagnosing these exciting developments. As the quantum world is probed beyond regimes of weak coupling and near-equilibrium, novel computational methods are required that can faithfully parameterise the peculiar entanglement patterns of physical quantum states in a scalable manner. The central goal of GaMaTeN is the design and application of tensor network methods for studying quantum lattice systems with gauge symmetries, the universal paradigm that governs high-energy particles as well as low-temperature condensed matter. A computational framework will be developed for targeting interacting gauge and matter degrees of freedom in conditions that are beyond the reach of the ubiquitous Monte Carlo sampling techniques. Equilibrium properties of phases with high baryonic densities as well as non-equilibrium dynamical effects such as the phenomenon of string breaking or the spontaneous particle production in strong external fields will be investigated. At the conceptual level, a unique entanglement perspective on the non-perturbative real-space scaling behaviour of gauge theories will be provided. Furthermore, the advancements in this proposal are essential in order for tensor networks to uphold their instrumental role in assisting and benchmarking future quantum simulation proposals and experiments. The tensor network algorithms developed in the GaMaTeN project will be optimised for high performance and will maximally exploit symmetries. They will be released as a general-purpose open-source library, which offers the potential for a lasting impact far beyond the scope of this proposal.

Keywords: tensor networks,gauge symmetry,quantum matter,renormalisation group,entanglement,computational physics
Designing a European Brain Health Landscape (CSA BrainHealth)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Coordination and support actions
Countries involved: Germany,France,Belgium,Spain,Italy,Romania,Taiwan, Province of China,Hungary,Portugal,Israel,Netherlands
Call: Towards structuring brain health research in Europe (HORIZON-HLTH-2023-DISEASE-03, 2023)
Start date: 2023-11-01
End date: 2025-10-31
Duration (months): 24.0
Total project cost (EUR): 1218550.0
EU funding (EUR): 1218550.0
Participants: 18
Project status: SIGNED

The Coordination and Support Action (CSA) BrainHealth will lay the ground for an envisaged ‘European Partnership (EP) on Brain Health’. Twenty participants from 11 Member and Associated States and Third countries will jointly pursue the work plan. The overall objective of the CSA is to sizeably contribute to maintenance and restoration of brain health for citizens in Europe and worldwide. Specifically, the project aims to design a collaboration framework for the EP as an umbrella for existing initiatives and stakeholder communities in this area. The CSA will create a common understanding of achievements, gaps and future developments in European research into brain health, and derive from them priorities and opportunities in a Strategic Research and Innovation Agenda (SRIA). Intense consultation with representatives of Member and Associated States is expected to lead to adoption of the SRIA and development of an implementation plan that will allow for strategic alignment of regional and national research programmes and commitments to the EP. Research infrastructures and platforms will be analysed regarding their service opportunities, and solutions will be developed to facilitate data and material sharing in the area of brain health. For highest possible impact, the CSA will reach out to the most relevant globally acting initiatives and their brain research strategies and policies. Synergies will be identified to shape the international landscape and establish new while maintaining existing collaboration. Finally, the CSA activities will be embedded in thoroughly planned dissemination and communication activities and an efficient management structure.

Keywords: neurological and psychiatric disorders,jpnd,neuron,ebc,ebrains,strategic research and innovation agenda,public and patient involvement,policy makers,research funding,stakeholders,era